Stocks Health care ALLO
NASDAQ · Health careAllogene Therapeutics, Inc. (ALLO)
It posted a net loss of $165.5M. In fiscal 2025 capital spending exceeded operating cash flow by $149.6M. At June 30, 2026 it held $38.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Allogene Therapeutics, Inc. does
Allogene Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALLO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$190.9M | -$0.87 | -$149.6M |
| 2024 | $22K | -$257.6M | -$1.32 | -$201M |
| 2023 | $95K | -$327.3M | -$2.09 | -$239.2M |
| 2022 | $156K | -$340.4M | -$2.38 | -$225.7M |
| 2021 | $114.1M | -$182.1M | -$1.34 | -$206.3M |
| 2020 | $0 | -$316.4M | -$2.63 | -$181.1M |
Latest SEC filings
What Allogene Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 2, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- June 22, 2026
- June 22, 2026
- May 28, 2026Additional proxy material DEFA14A
Questions about ALLO
What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALLO.
Is Allogene Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $165.5M.
When did Allogene Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 2, 2026.
Similar companies
Follow ALLO
Get an email when Allogene Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ALLO: get an email when it filesWhere the numbers come from
Financial figures are the values Allogene Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.